Founded in 1994 by Art Pappas, A. M. Pappas & Associates manages approximately $150 million in total committed capital. At our core is an experienced team of investment professionals deeply versed in science and medicine, who effectively leverage each other as well as key participants in AMP&A's network to support the development of our portfolio companies. Among our nearly 40 portfolio companies are Gene Logic (Nasdaq: GLGC), Arena Pharmaceuticals (Nasdaq: ARNA), Variagenics (Nasdaq: NUVO), AtheroGenics (Nasdaq: AGIX) and NuVasive (Nasdaq: NUVA). We are focused. We invest exclusively within the life science industry. We are relationship-oriented and performance-driven. Everything we do is about building and strengthening relationships and delivering exceptional value on behalf of our portfolio companies. We are employee-owned. Each of us at AMP&A has a stake in what we do and how well we do it.